1 APOE-ε4 and BIN1 increase risk of Alzheimer's disease pathology but not specifically

2 of Lewy body pathology

- 3 Seth Talyansky^{1†}, Yann Le Guen^{1,2*†}, Nandita Kasireddy¹, Michael E. Belloy¹, and Michael D. Greicius¹
- 4 ¹Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA
- 5 ²Institut du Cerveau Paris Brain Institute ICM, Paris, France
- 6 [†]Equal contributor
- 7 *Correspondence:
- 8 Department of Neurology and Neurological Sciences Greicius lab
- 9 Stanford University
- 10 290 Jane Stanford Way, E265, CA 94305-5090
- **11** Tel: 650 666 2696
- 12 Email: yleguen@stanford.edu

13 Abstract

Lewy body (LB) pathology commonly occurs in individuals with Alzheimer's disease (AD) pathology. 14 However, it remains unclear which genetic risk factors underlie AD pathology, LB pathology, or AD-15 16 LB co-pathology. Notably, whether APOE- $\varepsilon 4$ affects risk of LB pathology independently from AD 17 pathology is controversial. We adapted criteria from the literature to classify 4,985 subjects from the National Alzheimer's Coordinating Center (NACC) and the Rush University Medical Center as AD-LB 18 19 co-pathology (AD+LB+), sole AD pathology (AD+LB-), sole LB pathology (AD-LB+), or no pathology (AD-LB-). We performed a meta-analysis of a genome-wide association study (GWAS) per 20 subpopulation (NACC/Rush) for each disease phenotype compared to the control group (AD-LB-), 21 22 and compared the AD⁺LB⁺ to AD⁺LB⁻ groups. APOE- ε 4 was significantly associated with risk of AD⁺LB⁻ and AD+LB+ compared to AD-LB-. However, $APOE-\varepsilon 4$ was not associated with risk of AD-LB+ 23 24 compared to AD-LB- or risk of AD+LB+ compared to AD+LB-. Associations at the BIN1 locus exhibited 25 qualitatively similar results. These results suggest that APOE- $\varepsilon 4$ is a risk factor for AD pathology, but 26 not for LB pathology when decoupled from AD pathology. The same holds for *BIN1* risk variants. These findings, in the largest AD-LB neuropathology GWAS to date, distinguish the genetic risk 27 28 factors for sole and dual AD-LB pathology phenotypes. Our GWAS meta-analysis summary statistics, 29 derived from phenotypes based on postmortem pathologic evaluation, may provide more accurate 30 disease-specific polygenic risk scores compared to GWAS based on clinical diagnoses, which are 31 likely confounded by undetected dual pathology and clinical misdiagnoses of dementia type.

32 Introduction

Alzheimer's disease (AD) pathology has been the focus of many studies, but Lewy body (LB) 33 pathology has received less attention. In individuals with AD, LB pathology frequently co-occurs with 34 35 AD pathology, while LB pathology alone or accompanied by limited AD pathology is characteristic of Parkinson's disease (PD) and LB dementia [30, 53, 49, 54]. Genetic variants associated with AD 36 37 pathology, LB pathology, and/or AD-LB co-pathology remain to be distinguished. Characterizing each set of risk factors and any potential overlap will help clarify the etiology of AD and LB pathology. AD 38 39 pathology is found in 19–67% of older individuals at autopsy, depending on the population, the individual's age, and the diagnostic criteria used [44]. LB pathology is observed in 6–39% of older 40 individuals, but in 60% of individuals with AD pathology [44, 30, 34]. Positive classification for LB 41 42 pathology requires, at a minimum, the presence of α -synuclein-bearing Lewy bodies in the brainstem, 43 with further extension of LB pathology into the limbic system associated with the clinical diagnosis of dementia [38]. Positive classification for AD pathology requires the presence of tau neurofibrillary 44 tangles (NFTs) in the limbic system along with amyloid- β core neuritic plaques in the cortex [8, 39]. 45 Lewy bodies and NFTs spread to the cortex late in the progression of either pathology [38, 8]. Braak 46 47 staging is the primary scheme used to classify NFT progression, while the Consortium to Establish a 48 Registry for Alzheimer's Disease (CERAD) scoring is the primary scheme used to classify neuritic 49 plaque density. AD has traditionally been defined pathologically as Braak stage IV or higher, and at 50 least moderate CERAD [17], although some studies have used less stringent criteria (Braak stage III 51 or higher, and at least sparse CERAD) [28]. Thal phasing of amyloid- β non-neuritic plaques [51], based on another staging devised by Braak [9], has more recently been used as a third essential 52 53 metric to classify AD [11]. Of the five Thal phases, only the last two, in which plaques are present in 54 the brainstem and cerebellum, are specific to dementia patients [17].

55 Clinical diagnoses of AD and LB dementia are challenging and error-prone in comparison to the gold 56 standard of a pathologic diagnosis [19]. However, most study participants have only been clinically diagnosed due to the scarcity of postmortem pathologically confirmed data. In a study of 919 57 58 autopsied individuals comparing clinical diagnosis of AD to pathological diagnosis, the diagnosis of 59 clinically probable AD had an 83% positive predictive value (PPV) for pathological criteria of Braak 60 state III or higher and moderate/high CERAD [1]. This study was conducted before AD biomarkers like spinal fluid amyloid and tau levels, or amyloid and tau PET scans, were more commonly used, so 61 the PPV of the clinical diagnosis is now likely higher than 83%; however, it remains imperfect. The 62 PPV for a clinical diagnosis of probable LB dementia against the pathologic diagnosis is also around 63 80% [21, 50, 45]. In general, it has been difficult to clinically distinguish between AD without Lewy 64

bodies, AD with Lewy bodies, and LB dementia [25]. Additionally, individuals who may have
advanced pathology, but mild symptoms are frequently misdiagnosed clinically or missing from
clinical datasets altogether because they do not seek medical attention.

Motor function and neuropsychiatric and cognitive symptoms have been suggested as diagnostic 68 clues of AD pathology, LB pathology, or co-pathology [14, 48]. Moreover, developing AD pathology 69 70 biomarkers such as assays of amyloid-β, tau, and phosphorylated tau levels in the cerebrospinal fluid 71 or blood plasma has been valuable in closing the gap between diagnosis during life and pathologic 72 AD diagnosis [6, 32]. LB pathology biomarkers, including promising assays of α -synuclein aggregates 73 in the cerebrospinal fluid, are similarly improving the diagnosis of LB dementia [47, 43, 36]. Still, 74 because LB biomarkers have been developed more recently, most existing genetic datasets consist of 75 only clinically diagnosed subjects. Ultimately, as a histological and molecular endophenotype, 76 pathologic diagnosis offers the most reliable insights into the genetic drivers of disease. 77 Previous research has produced contrasting and somewhat ambiguous findings on the genetic risk

78 loci for AD and LB pathology. This could be because most studies include only clinically assessed 79 subjects or have relatively few pathologically assessed subjects. Importantly, most prior studies on 80 AD and LB pathology, even with pathologic confirmation, do not stratify subjects into distinct groups 81 for sole AD pathology (AD+LB-), LB pathology (AD-LB+), co-pathology (AD+LB+), and neither 82 pathology (AD-LB-), making the results difficult to accurately interpret. It is well known that the $\varepsilon 4$ 83 allele of the *Apolipoprotein E (APOE)* gene is the strongest common genetic risk factor for AD [4, 31]. 84 However, various studies have reported that APOE- $\varepsilon 4$ is also associated with increased risk of sole 85 LB pathology (AD-LB⁺) [52, 18], LB dementia [5, 2, 24, 48, 13], or increased risk of AD-LB co-86 pathology (AD+LB+) in AD individuals [14]. Walker and Richardson (2023) found that APOE- ε 4 was 87 associated with AD, LB, or limbic-predominant age-related TDP-43 encephalopathy pathology as well 88 as with the presence of multiple of these pathologies [54]. This suggests that APOE- $\varepsilon 4$ could be 89 associated with AD-LB⁺ pathology.

How APOE- $\varepsilon 4$ affects the severity of LB pathology has also been investigated. Studies reported that 90 91 α -synuclein pathology mouse models expressing APOE- ε 4 develop more extensive inclusions [22, 92 16]. In humans, LB pathology was found to be more severe among APOE- ε 4 carriers independent of 93 AD pathology severity [23], as well as among APOE- ε 4-carrying AD-LB⁺ subjects relative to non-94 carriers [18, 22, 57]. However, when Kaivola et al. (2022) categorized pathologically confirmed cases 95 from the cohort in [13] by not only LB but also AD pathology status, APOE- ε 4 was not associated with risk of AD-LB+ pathology [28]. Robinson *et al.* (2018) found that APOE- ε 4 was associated with cortical 96 97 LB co-pathology (cortical LB pathology accompanied by an amyloidopathy, tauopathy, or TDP-43

- 98 proteinopathy) compared to sole LB pathology; however, *APOE*-ε4 was not associated with AD-LB
- 99 co-pathology compared to sole AD pathology [46]. Furthermore, Dickson *et al.* (2018) found that
- 100 *APOE*-ε4 was not associated with more severe LB pathology in individuals with moderate or high AD
- 101 pathology [18]. It, therefore, remains unclear whether *APOE*- ε 4 in fact increases risk of AD-LB⁺ 102 pathology.
- 103 Importantly, beyond APOE- ε 4, there may be other pathology-specific genetic risk loci yet to be 104 identified. Along this line, it is relevant to note that removing individuals that are not pathologically
- 105 evaluated from study cohorts has been shown to reduce noise in genome-wide association studies
- 106 (GWAS) and to improve polygenic risk score analyses of AD [15, 20, 19]. These observations
- 107 emphasize the need for novel GWAS of AD/LB pathology to better characterize the genetic
- 108 architecture of these complex dementias.
- 109 To this end, we assembled a preliminary cohort of 5,254 individuals with genetic data and autopsy-
- 110 confirmed AD and LB pathology status, the largest such cohort to date. We adapted criteria from the
- 111 literature to categorize these individuals as AD+LB+, AD+LB-, AD-LB+, or AD-LB-, yielding 1,072
- 112 AD+LB+, 2,492 AD+LB-, 158 AD-LB+, and 1,263 AD-LB- individuals in our study cohort (total N =
- 113 4,985). We compared each disease category to controls by performing separate GWAS meta-analyses.
- 114 We also compared AD⁺LB⁺ pathology to AD⁺LB⁻ pathology in another analysis.

115 Materials and methods

116 Study cohort

- 117 We analyzed data from individuals from the National Alzheimer's Coordinating Center (NACC) and 118 Rush University Medical Center databases who were evaluated postmortem for both AD and LB 119 pathology. We excluded NACC individuals who were classified as having Lewy bodies in the olfactory 120 bulb or in an "unspecified" region (individuals for whom the NACCLEWY parameter was equal to 4). We also excluded individuals missing sex or age-at-death information. In total, our preliminary 121 122 cohort comprised 5,254 individuals before classification according to AD and LB pathology status. 123 This cohort was distinct from that analyzed in [13], the largest genetic study of LB dementia (which included subjects without pathology verification), and [28], the largest previous genetic study of 124 125 subjects categorized by both AD and LB pathology status. 126 Pathological criteria We classified individuals as having both AD and LB pathology (AD⁺LB⁺), AD pathology only (AD⁺LB⁻ 127 128), LB pathology only (AD⁻LB⁺), or neither pathology (AD⁻LB⁻) (**Fig. 1**). Individuals who could not be classified using our criteria were excluded (**Fig. 1c**). In sensitivity analyses, we applied the pathology 129 criteria from [52] and [28] to our preliminary cohort (Fig 1. a-b). Criteria were set as follows for LB 130 131 pathology. 132 LB⁺ pathology were individuals with Lewy bodies spread to the limbic system or cortex, as in [28] and [52]. 133 LB- pathology were individuals with no Lewy bodies or Lewy bodies limited to the brainstem, 134 as in [28], but not in [52], which excluded individuals with brainstem-limited Lewy bodies. 135 Some gray zones, representing rare subcategories with unclassified individuals, are defined 136
- based on Braak stage and CERAD score below.
 Criteria for AD pathology were less straightforward because of borderline subcategories and possible

139 confounding with other pathologies. In agreement with [28] and [52] (**Fig. 1**),

- AD+ pathology included individuals with Braak stage IV or higher and CERAD score moderate
 or frequent.
- AD- pathology included individuals with Braak stage II or lower, or Braak stage III/IV and
 CERAD score absent.

Other subcategories were largely classified differently between [28] and [52], and we settled on the
following criteria. First, we defined three gray zones of unclassified individuals corresponding to rare
pathologic profiles (N = 269 total).

Individuals who had Braak stage V/VI and CERAD score absent, regardless of LB category,
 were not classified for the reason of likely having a rare tauopathy distinct from AD [41].

- Similarly, individuals with absent or brainstem Lewy bodies (LB-) who had Braak stage V/VI
 and CERAD score sparse were not classified.
- Braak stage III and CERAD score frequent in LB- individuals were insufficient for classification as AD+, but too high for a confident classification as AD-. Ultimately, our goal was to obtain a clean control (AD-LB-) group.

Second, certain borderline subcategories were classified differently (AD+ or AD-) depending on LB
category.

- Individuals with absent or brainstem Lewy bodies (LB-) were AD- for Braak stage III and
 CERAD score sparse or moderate; or Braak stage IV and CERAD score sparse.
- Individuals with limbic or cortical Lewy bodies (LB+) were AD+ for Braak stage III or higher
 and CERAD score sparse; or Braak stage III and CERAD score moderate or frequent.

160 Using our criteria (**Fig. 1c**), we categorized our preliminary cohort into 1,072 AD+LB+, 2,495 AD+LB-,

161 158 AD-LB+, and 1,263 AD-LB- individuals; these 4,985 individuals formed our study cohort (**Table**

162 1). Overall, the set of four phenotypes was better represented in our study than in previous studies

(Suppl. Table 1), which stratified subjects less completely or had fewer individuals in total (Tsuang*et al.*).

165 Genome-wide analysis

166 We performed a meta-analysis of separate GWAS in the NACC and Rush subsets of our cohort for each of AD+LB+, AD+LB-, and AD-LB+ pathology compared to AD-LB- pathology, as well as for AD+LB+ versus 167 AD⁺LB⁻ pathology. We used PLINK 2.0 for logistic regression and included sex, age-at-death, and the 168 top ten principal components accounting for genetic ancestry as covariates [11]. We removed 169 duplicates and first-degree relatives within and between genomic datasets using KING [37]. In each 170 171 pair of relatives, the relative with younger age at death was preferentially kept or the oldest control 172 in the absence of pathology cases. We filtered out genetic variants that had a minor allele frequency below 0.01, departed from Hardy-Weinberg equilibrium with a significance below $P < 10^{-5}$, or had a 173 174 missingness rate above 20%. We imputed data on the TOPMed reference panel as described in [33] 175 and considered variants with $R^2 > 0.8$. We meta-analyzed the separate NACC and Rush GWAS using 176 the inverse variance weighted method in METAL [55]. Manhattan plots from summary statistics were 177 produced using the R package CMplot [56]. The significance threshold was set at $P < 5 \times 10^{-8}$, the 178 standard threshold for genome-wide significance. We estimated the association of APOE- $\varepsilon 4$ with risk 179 of AD+LB+, AD+LB-, and AD-LB+ pathology relative to AD-LB- pathology, and the association with risk

- 180 of AD+LB+ pathology relative to AD+LB- pathology, in terms of odds ratio (OR). We also estimated the
- association of *APOE*-ε2. We compared our estimates to those in the literature [52, 28, 13, 2, 10, 14,
- 182 18, 46, 48] and when relevant we computed measures of linkage disequilibrium between variants in
- 183 European ancestry populations using LDlink [35]. We examined loci besides APOE that led to
- 184 genome-wide significant signals. We explored lead variant annotation at significant loci using
- 185 gnomAD [45]. Finally, we surveyed AD and PD risk loci reported in large clinical case-control GWAS
- 186 [3, 12, 40] and report the ones associated with pathology at the nominal significance level (P < 0.05)
- in our study.

188 **Results**

We observed that $APOE \epsilon 4$ (rs429358) was associated with risk of AD+LB+ pathology versus AD-LB-189 pathology (OR = 4.24, 95% CI = 3.52-5.10, $P = 1.5 \times 10^{-52}$) and risk of AD+LB- pathology versus AD-190 LB⁻ pathology (OR = 4.22, 95% CI = 3.60–4.96, $P = 1.4 \times 10^{-69}$) (Fig. 2a–b; Table 4). We did not 191 192 observe an association of APOE- $\varepsilon 4$ with the risk of AD-LB⁺ pathology versus AD-LB⁻ pathology (OR = 193 0.93, 95% CI = 0.60–1.43, *P* = 0.73) or risk of AD+LB+ pathology versus AD+LB- pathology (OR = 1.01, 95% CI = 0.90-1.13, P = 0.83) (Fig. 2c-d; Table 4). Another gene locus that yielded significant 194 195 associations was BIN1. Like APOE-E4, we observed that rs4663105 on the BIN1 locus was associated with risk of AD+LB- pathology compared to AD-LB- pathology (OR = 1.40, 95% CI = 1.26–1.56, P = 6.5196 197 \times 10⁻¹⁰) and risk of AD+LB+ pathology compared to AD-LB- pathology (OR = 1.53, 95% CI = 1.35–1.75, 198 $P = 1.4 \times 10^{-10}$ (Fig. 2a-b; Table 5). rs4663105 was not observed to be associated with risk of AD-199 LB⁺ pathology versus AD⁻LB⁻ pathology (OR = 1.10, 95% CI = 0.85–1.41, *P* = 0.48) or risk of AD⁺LB⁺ pathology versus AD+LB- pathology (OR = 1.13, 95% CI = 1.02-1.25, P = 0.019) at the genome-wide 200 significance level (**Fig. 2c-d; Table 5**). When using pathological criteria from Tsuang *et al.* (2013) 201 (Fig. 1a), effect estimates for APOE- ε 4 differed considerably from those reported in the original 202 203 study, particularly so for the effect on AD-LB+ vs. AD-LB- (**Table 4**). On the contrary, there was fair 204 agreement when using pathological criteria from Kaivola *et al.* (2022) (Fig. 1b; Table 4). APOE- $\varepsilon 2$ 205 showed similar results to *APOE*- ε 4, except with the opposite direction of effect in the GWAS where *APOE*- ε 4 exhibited an association (**Suppl. Table 3**). Overall, we observed an enrichment among the 206 207 79 variants listed in the clinical AD GWAS (Bellenguez et al. (2022)) and tested in our analyses; we observed an enrichment of nominally significant associations with concordant direction of effect: 208 209 20.3% variants (16/79) in the AD+LB- vs. AD-LB- contrast and 24.1% (19/79) in the AD+LB+ vs. AD-210 LB- (with the chance level being at 2.5%). In contrast, we did not observe a significant enrichment 211 for the 76 variants identified in PD clinical GWAS Chang et al. (2017) and Nalls et al. (2019): 2.6% (2/76) in the AD+LB+ vs. AD-LB- contrast, 3.9% (3/76) in the AD-LB+ vs. AD-LB- contrast, and 2.6% 212 (2/76) in the AD+LB+ vs. AD+LB- contrast. Among known AD risk loci besides BIN1 and APOE reported 213 by Bellenguez et al. (2022), ADAM17 (rs72777026), COX7C (rs62374257), HLA (rs6605556), TREM2 214 (rs143332484), HS3ST5 (rs785129), SEC61G (rs76928645), CLU (rs11787077), ECHDC3 215 216 (rs7912495), TPCN1 (rs6489896), FERMT2 (rs17125924), DOC2A (rs1140239), PRDM7 217 (rs56407236), ABI3 (rs616338), ABCA7 (rs12151021), and SIGLEC11 (rs9304690) were concordant and nominally associated with AD+LB+ versus AD-LB-; and CR1 (rs679515), ADAM17 (rs72777026), 218 INPP5D (rs10933431), CLNK/HS3ST1 (rs6846529), ANKH (rs112403360), COX7C (rs62374257), 219 220 HLA (rs6605556), TREM2 (rs143332484), ZCWPW1/NYAP1 (rs7384878), PTK2B (rs73223431),

CLU (rs11787077), ECHDC3 (rs7912495), PICALM (rs3851179), SORL1 (rs11218343), FERMT2 221 222 (rs17125924), APH1B (rs117618017), MAF (rs450674), and ABCA7 (rs12151021) were concordant 223 and nominally associated with AD+LB- pathology versus AD-LB- (Table 6; Suppl. Table 5). Among 224 known PD risk loci reported by Chang et al. (2017) and Nalls et al. (2019), SCN3A (rs353116) and 225 *HLA-DRB6/HLA-DOA1* (rs9275326) were concordant and nominally associated with AD⁺LB⁺ versus 226 AD-LB-; TMEM175/DGKQ (rs34311866), FAM200B/CD38 (rs11724635), and SNCA (rs356182) were 227 concordant and nominally associated with AD-LB⁺ versus AD-LB⁻; and GBA (rs35749011) and 228 TMEM175/DGKQ (rs34311866) were concordant and nominally associated with AD+LB+ versus 229 AD⁺LB⁻ (Table 6; Suppl. Table 5). Notably, the *TPCN1* locus, reported to be associated with LB 230 dementia by Kaivola et al. (2023), was associated with AD+LB+ pathology and AD+LB- pathology 231 versus AD-LB- pathology below or near the nominal significance level, but not so with AD-LB+ 232 pathology versus AD-LB- pathology or AD+LB+ pathology versus AD+LB- pathology.

233 **Discussion**

Our study emphasizes that APOE- ε 4 is associated with the risk of both AD+LB- pathology (OR = 4.22, 234 $P = 1.4 \times 10^{-69}$ and AD+LB+ co-pathology (OR = 4.24, $P = 1.5 \times 10^{-52}$) compared to AD-LB- pathology. 235 236 These OR estimates were lower than the estimates in Tsuang *et al.* for APOE-*ɛ*4-associated risk of 237 AD⁺LB⁻ pathology (OR = 12.6, $P = 2.1 \times 10^{-28}$) and AD⁺LB⁺ co-pathology (OR = 9.9, $P = 1.2 \times 10^{-24}$) 238 (Table 4) [52]. Tsuang *et al.* appear to have overestimated the true effect size of APOE- ε 4 in their positive pathology subjects, possibly due to the smaller size of their cohort [52] (N = 640 versus N =239 240 4,985 in the current study) (**Table 3**). Our estimate of APOE- ε 4-associated risk for AD+LB+ pathology 241 is in line with the estimate in Kaivola *et al.*, the next largest study of pathologically assessed 242 individuals (OR = 4.25, $P = 1.29 \times 10^{-32}$) [28]. Our data substantiate that *APOE*- ε 4 is a driver of AD 243 pathology. Notably, we estimated a similar effect size of $APOE \cdot \epsilon 4$ on the risk of AD+LB- pathology (OR 244 = 4.22) and on the risk of AD+LB+ co-pathology (OR = 4.24) versus AD-LB- pathology, suggesting that *APOE*- ε 4 does not have a specific effect on the development of LB pathology in individuals with AD 245 246 pathology. Consistent with this finding, we did not observe APOE- $\varepsilon 4$ to be associated with the risk of AD+LB+ co-pathology compared to sole AD+LB- pathology (OR = 1.01, P = 0.83). 247

This finding contradicts the results presented by Chung *et al.* (2015), where $APOE \cdot \epsilon 4$ was found to 248 249 be associated with AD⁺LB⁺ co-pathology when compared to sole AD⁺LB⁻ pathology (P = 0.03) [14]. 250 However, their AD⁺LB⁺ group was five times smaller than ours (N = 215 versus N = 1,072), and the AD+LB- group was eight times smaller (N = 316 versus N = 2,492). Our result is consistent with the 251 finding in Robinson *et al.* (2018) that APOE- ε 4 is not associated with the co-occurrence of AD 252 pathology with other pathologies (OR = 0.71, P = 0.64 for intermediate AD pathology; and OR = 0.93, 253 254 P = 0.83 for high AD pathology [46]. Our result is also consistent with the finding in Dickson *et al.* 255 (2018) that APOE- ε 4 is not associated with higher Lewy body count in individuals with moderate AD 256 pathology ($P \ge 0.30$ for all regions) or high AD pathology ($P \ge 0.069$ for all regions) [18]. Taken 257 together, APOE- ε 4 appears similarly prevalent in AD pathology cases with or without LB pathology. Furthermore, we did not find APOE- ε 4 to be associated with risk for sole LB pathology (AD-LB+) 258 pathology (OR = 0.93, P = 0.73) compared to no pathology (AD-LB-). This is in contradiction with [52] 259 where *APOE*- ε 4 was strongly associated with risk for AD-LB+ pathology (OR = 6.1, *P* = 1.3 × 10⁻¹⁰). 260 261 This discrepancy could be because Tsuang *et al.* used a more stringent definition of AD pathology 262 (**Fig. 1a**), leaving open the possibility that individuals whom we would have classified as AD⁺LB⁺ with

our criteria were instead classified as AD⁻LB⁺. Indeed, when we categorized our initial pathologically
evaluated cohort using the exact same criteria as in [52], testing the association of *APOE*-ε4 with risk

of AD-LB+ pathology yielded a modestly higher OR and nominal significance (OR = 1.46, $P = 5.5 \times$

10⁻³) (**Table 4**). The main difference between our criteria and those of Tsuang *et al.* is that we lower the threshold for AD pathology to Braak stage III NFTs plus sparse neuritic plaques in LB⁺ individuals, suggesting that LB pathology commonly occurs in *APOE*- ε 4 carriers with potential early-stage AD but not in firmly non-AD *APOE*- ε 4 carriers. Knowing the breakdown of the *APOE*- ε 4-positive subjects in [52] by Braak stage and CERAD score would establish further support for this interpretation.

- 271 Dickson et al. also found an association of APOE-E4 with the risk of diffuse LB pathology and low AD 272 pathology (OR = 3.46, P = 0.001) while classifying individuals with Braak stage III NFTs and Thal 273 phase 0, 1, or 2 amyloid- β non-neuritic plaques as having low AD pathology [18]. In this AD-LB+ 274 group, the median Braak stage was III and the median Thal phase was 1. We would have classified 275 this subset as AD+LB+. A Thal phase of 1 tends to correspond to a CERAD score of sparse neuritic 276 plaques or higher [7]. Therefore, many individuals in this AD-LB⁺ group in [18] had a Braak stage of 277 III and at least sparse neuritic plaques; this subset was likely the source of the elevated frequency of 278 *APOE*- ε 4 in the group. We would have classified this subset as AD⁺LB⁺ instead. It should be noted that 279 this AD-LB⁺ group in Dickson *et al.* was smaller than ours (N = 54 versus N = 158) and the controls were not pathologically confirmed. Another cause of the discrepancy between our result that APOE-280 281 ϵ 4 was not associated with the risk of AD-LB+ pathology and Tsuang *et al.*'s finding that *APOE*- ϵ 4 282 increased risk for LB pathology may have been that the pathologically confirmed AD-LB- group in [52] was more than four times smaller than ours (N = 269 versus N = 1,263). Remarkably, the 283 284 frequency of *APOE*- ε 4 was 31.9% in the AD-LB⁺ group [52], which was far higher than in our AD-LB⁺ 285 group (8.9%). Our result was consistent with the finding in Dickson *et al.* that APOE- ε 4 was not associated with the risk of the AD-LB+ phenotype of transitional (limbic) LB pathology and low AD 286 pathology (OR = 0.73, P = 0.31) [18]. 287
- In a larger study than [52] of pathologically confirmed LB dementia cases and mixed pathologic and 288 clinical controls, Chia *et al.* found that $APOE - \varepsilon 4$ was associated with risk of LB dementia: OR = 2.45 289 290 with $P = 4.65 \times 10^{-63}$ for rs769449, which is in linkage disequilibrium with *APOE*- ε 4 with $R^2 = 0.766$ 291 [13]. However, this could have been because Chia *et al.* did not categorize individuals by AD pathology status, and many AD+LB+ individuals were inevitably included in the LB+ case group. When Kaivola et 292 293 *al.* studied the cohort in Chia *et al.* using more precise pathological categorization, *APOE*- ε 4 was not observed to have a significant effect on risk for AD-LB+ pathology (OR = 0.75, P = 0.31) [28]. 294 Associations of *APOE*- ε 4 with risk of LB pathology (OR = 1.63, *P* = 2.8 × 10⁻¹¹) and LB dementia (OR 295 296 = 2.71, $P = 7.1 \times 10^{-35}$; OR = 2.40, $P = 1.05 \times 10^{-48}$; and OR = 2.94, $P = 6.6 \times 10^{-20}$) reported in Beecham 297 et al. (2014), Bras et al. (2014), Guerreiro et al. (2018), and Sabir et al. (2019), respectively, could 298 similarly have been because these studies did not exclude AD+LB+ individuals from their LB+ case

groups [2, 10, 24, 48]. Our finding was also consistent with the result in Robinson *et al.* that *APOE-* ε 4 was associated with the co-occurrence of cortical LB pathology with other pathologies, including AD pathology, versus sole cortical LB pathology (OR = 9.32, *P* = 0.003) [46]. The latter result would imply that *APOE-* ε 4 was rarer in the AD-LB⁺ individuals in [46] than in LB⁺ individuals with advanced LB pathology. Presumably, because 80% of LB⁺ individuals also had AD pathology, the prevalence of *APOE-* ε 4 in LB⁺ individuals was most likely unrelated to the presence of LB pathology.

305 The balance of evidence thus suggests that APOE- $\varepsilon 4$ does not affect risk for AD-LB⁺ pathology when 306 strictly defined to exclude possible early-stage AD. Subjects with LB pathology and no AD pathology 307 have been rare, and more are needed to substantiate this conclusion. This concept does not oppose 308 the observations in Dickson et al. and Zhao et al. (2020) that APOE-E4 was associated with higher LB 309 counts in AD-LB⁺ subjects, as neither analysis compared cases to controls without pathology [18, 57]. Similarly compatible is the observation in Goldberg *et al.* (2020) that *APOE-* ε 4 was associated with 310 311 further propagated Lewy bodies; although Goldberg et al. adjusted for AD pathology level, their 312 analysis did not specifically compare LB⁺ to LB⁻ subjects [23]. It is conceivable that *APOE*- ε 4 worsens 313 LB pathology but does not influence its actual emergence in individuals without AD pathology. Overall, our data suggest APOE- $\varepsilon 4$ is most likely not involved in the emergence of LB pathology in the 314 315 absence or presence of AD pathology. This interpretation is further supported by the lack of an effect of *APOE*- ε 4 in the largest GWAS of clinically defined PD (OR = 1.02, *P* = 0.49) [40]. 316

A second gene locus that yielded significant associations was *BIN1*. As for *APOE-* ε 4, the *BIN1* lead 317 318 variant was associated with the risk of sole AD (AD+LB-) and AD+LB+ co-pathology, but not sole LB (AD-LB+) when compared to no pathology (AD-LB-). BIN1 was also not associated with the risk of 319 $AD^{+}LB^{+}$ co-pathology when compared to sole AD pathology ($AD^{+}LB^{-}$) pathology. These results further 320 corroborate that *BIN1* is also a driver of AD pathology. In the largest previous GWAS of LB pathology, 321 Chia *et al.* found that *BIN1* is a risk locus for pathologically confirmed LB dementia (OR = 1.25, P = 1.25322 4.16×10^{-9} for rs6733839, in linkage disequilibrium with rs4663105 with $R^2 = 0.8968$) [13]. 323 324 However, when gathering individuals, Chia *et al.* did not select against AD pathology, which was presumably far more prevalent in the LB⁺ case group than in the control group. Given that we do not 325 326 observe an association of rs4663105 with risk for AD-LB⁺ pathology, the *BIN1* association reported 327 in [13] may have been driven by the AD+LB+ subgroup within the LB+ group. However, our findings are limited by the size of our AD-LB⁺ group (N = 158); the lower statistical power of the AD-LB⁺ 328 329 pathology versus AD-LB- pathology GWAS was likely also the reason that known synucleinopathy 330 risk loci like *GBA* and *SNCA* did not yield genome-wide significant associations in this analysis. Altogether, the current balance of evidence suggests that variants on the BIN1 locus behave like 331

APOE-ε4: pathogenic BIN1 variants increase the overall risk of LB pathology simply by increasing the
 risk of AD pathology (which is frequently accompanied by LB pathology), but they do not affect the
 risk of AD-LB+ pathology or the risk of co-pathology (AD+LB+) among AD+ individuals. It is worth
 mentioning that the effect of BIN1 on the risk of AD pathology may be lifestyle-dependent, as we did
 not observe any association of BIN1 with pathology in the subset of Rush individuals alone (Suppl.
 Fig. 2; Suppl. Table 4). The monastic life of these subjects likely militates against disease.

Future studies should continue the effort of determining the risk loci for AD pathology, LB pathology, or AD-LB co-pathology using pathologically well-categorized and clinically unbiased cohorts. It may be worth focusing on comparing AD+LB+ to AD+LB- groups to identify LB pathology risk loci because the sample size of either phenotype is larger than AD-LB+. Further study of the AD+LB+ versus AD+LBand AD-LB+ versus AD-LB- contrasts may also reveal possible differences between genetic risk factors underlying LB pathology in the presence or absence of AD pathology; we propose a hypothetical genetic model in **Suppl. Fig. 3**.

345

346 Conclusion

In conclusion, our set of GWAS meta-analyses indicates that while APOE- $\varepsilon 4$ is a risk factor for AD 347 pathology and increases risk of AD-LB co-pathology, it is not a risk factor for LB pathology 348 349 independent of AD pathology or along with AD pathology. This is also true of variants on the BIN1 350 locus; therefore, neither APOE- $\varepsilon 4$ nor BIN1 variants appear to play a specific mechanistic role in the 351 emergence of LB pathology. We provide GWAS meta-analysis summary statistics that will enable more reliable, pathologically precise polygenic risk score calculations for AD, LB dementia, and 352 related disorders. Ultimately, we shed light on the genetic bases of AD and LB pathology, which will 353 354 be useful for further unraveling the etiology of these debilitating pathologies and developing accurate 355 and effective interventions.

356 Acknowledgments

This research is based on data collected by the National Alzheimer's Coordinating Center and theRush University Medical Center.

359

360 Funding

This work was supported by the National Institute on Aging grants 1R01-AG060747 (MDG) and K99AG075238 (MEB), the European Union's Horizon 2020 Research and Innovation Program under the Marie Skłodowska-Curie Actions grant 890650 (YLG), and the Alzheimer's Association grant

364 365

366 Availability of data and materials

AARF-20-683984 (MEB).

- 367 The summary statistics from our genome-wide association study meta-analyses are available online
- 368 (URL to NIAGADS and EBI GWAS catalogue to be updated at publication).
- 369

370 Authors' contributions

- 371 Concept and design: YLG, MDG. Data analysis: ST and YLG. Drafting of the manuscript: ST, YLG, NK,
- 372 MDG. Critical review of the manuscript: ST, YLG, NK, MEB, and MDG. Funding acquisition: YLG, MEB,
- and MDG.
- 374
- 375 Declarations

376 **Competing interests**

- 377 The authors declare that they have no competing interests.
- 378

379 Ethical approval and consent to participate

Participants or their caregivers provided written informed consent in the original studies. The
current study protocol was granted an exemption by the Stanford University institutional review
board because the analyses were carried out on deidentified data; therefore, additional informed
consent was not required.

- 385
- 386
- 387
- 388

389 References

- Beach TG, Monsell SE, Phillips LE, Kukull W (2012) Accuracy of the Clinical Diagnosis of
 Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. J
- 392 Neuropathol Exp Neurol 71:266–273. https://doi.org/10.1097/NEN.0b013e31824b211b
- Beecham GW, Hamilton K, Naj AC, Martin ER, Huentelman M, Myers AJ et al (2014) Genome wide association meta-analysis of neuropathologic features of Alzheimer's disease and
 related dementias. PLoS Genet 10. https://doi.org/10.1371/journal.pgen.1004606
- 396 3. Bellenguez C, Küçükali F, Jansen IE et al (2022) New insights into the genetic etiology of
 397 Alzheimer's disease and related dementias. Nat Genet 54:412-436.
 398 https://doi.org/10.1038/s41588-022-01024-z
- 399 4. Belloy ME, Napolioni V, Greicius MD (2019) A Quarter Century of APOE and Alzheimer's
 400 Disease: Progress to Date and the Path Forward. Neuron 101:820–838.
 401 https://doi.org/10.1016/j.neuron.2019.01.056
- 402 5. Berge G, Sandro SB, Ronge A et al (2014) Apolipoprotein E ε2 genotype delays onset of
 403 dementia with Lewy bodies in a Norwegian cohort. J Neurol Neurosurg Psychiatry 85:1227–
 404 1231. https://doi.org/10.1136/jnnp-2013-307228
- Blennow K, Zetterberg H (2018) Biomarkers for Alzheimer's disease: current status and
 prospects for the future. J Intern Med 284:643–663. https://doi.org/10.1111/joim.12816
- 407 7. Boluda S, Toledo JB, Irwin DJ et al (2014) A comparison of Aβ amyloid pathology staging
 408 systems and correlation with clinical diagnosis. Acta Neuropathol 128:543–550.
 409 https://doi.org/10.1007/s00401-014-1308-9
- 8. Braak H, Alafuzoff A, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer
 disease-associated neurofibrillary pathology using paraffin sections and
 immunocytochemistry. Acta Neuropathol 112:389–404. https://doi.org/10.1007/s00401006-0127-z
- Braak H, Braak E (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18:351–357. https://doi.org/10.1016/s0197-4580(97)00056-0
- 416 10. Bras J, Guerreiro R, Darwent L, Parkkinen L, Ansorge O et al (2014) Genetic analysis
 417 implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with
 418 Lewy bodies. Hum Mol Genet 23:6139–6146. https://doi.org/10.1093/hmg/ddu334
- 419 11. Chang CC, Chow CC, Tellier LCAM, Vattikuti S, Purcell SM, Lee JJ et al (2015) Second420 generation PLINK: rising to the challenge of larger and richer datasets. GigaScience 4.
 421 https://doi.org/10.1186/s13742-015-0047-8
- 422 12. Chang D, Nalls M, Hallgrímsdóttir I et al (2017) A meta-analysis of genome-wide association
 423 studies identifies 17 new Parkinson's disease risk loci. Nat Genet 49:1511–1516.
 424 https://doi.org/10.1038/ng.3955
- 425 13. Chia R, Sabir MS, Bandres-Ciga S, Saez-Atienzar S, Reynolds RH et al (2021) Genome
 426 sequencing analysis identifies new loci associated with Lewy body dementia and provides
 427 insights into its genetic architecture. Nat Genet 53:294–303.
 428 https://doi.org/10.1038/s41588-021-00785-3

- 429 14. Chung EJ, Babulal GM, Monsell SE, Cairns NJ, Roe CM, Morris JC et al (2015) Clinical Features
 430 of Alzheimer Disease With and Without Lewy Bodies. JAMA Neurol 72:789–796.
 431 https://doi.org/10.1001/jamaneurol.2015.0606
- 432 15. Corneveaux JJ, Myers AJ, Allen AN, Pruzin JJ, Ramirez M et al (2010) Association of CR1, CLU
 433 and PICALM with Alzheimer's disease in a cohort of clinically characterized and
 434 neuropathologically verified individuals. Hum Mol Genet 19:3295–3301.
 435 https://doi.org/10.1093/hmg/ddq221
- 436 16. Davis AA et al (2020) APOE genotype regulates pathology and disease progression in
 437 synucleinopathy. Sci Transl Med 12. https://doi.org/10.1126/scitranslmed.aay3069
- 438 17. DeTure MA, Dickson DW (2019) The neuropathological diagnosis of Alzheimer's disease. Mol
 439 Neurodegeneration 14. https://doi.org/10.1186/s13024-019-0333-5
- 440 18. Dickson DW, Heckman MG, Murray ME, Soto AI, Walton RL et al (2018) APOE ε4 is associated
 441 with severity of Lewy body pathology independent of Alzheimer pathology. Neurology
 442 91:1182-1195. https://doi.org/10.1212%2FWNL.0000000006212
- 443 19. Escott-Price V, Hardy J (2022) Genome-wide association studies for Alzheimer's disease:
 444 bigger is not always better. Brain Commun 4:125.
 445 https://doi.org/10.1093/braincomms/fcac125
- 20. Escott-Price V, Myers AJ, Huentelman M, Hardy J (2017) Polygenic Risk Score Analysis of
 Pathologically Confirmed Alzheimer Disease. Ann Neurol 82:311–314.
 https://doi.org/10.1002/ana.24999
- 449 21. Ferman TJ, Boeve BF, Smith GE, Lin SC, Silber MH et al (2011) Inclusion of RBD improves the
 450 diagnostic classification of dementia with Lewy bodies. Neurology 77:875–882.
 451 https://doi.org/10.1212/WNL.0b013e31822c9148
- 452 22. Fyfe I (2020) APOE*ε4 promotes synucleinopathy. Nat Rev Neurol 16.
 453 https://doi.org/10.1038/s41582-020-0335-5
- 454 23. Goldberg TE, Huey ED, Devanand DP (2020) Association of APOE e2 genotype with
 455 Alzheimer's and non-Alzheimer's neurodegenerative pathologies. Nat Commun 11.
 456 https://doi.org/10.1038/s41467-020-18198-x
- 457 24. Guerreiro R, Ross OA, Kun-Rodrigues C, Hernandez DG, Orme T et al (2018) Investigating the
 458 genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association
 459 study. Lancet Neurol 17:64–74. https://doi.org/10.1016/s1474-4422(17)30400-3
- 460 25. Hohl U, Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J (2000) Diagnostic Accuracy of
 461 Dementia With Lewy Bodies. Arch Neurol 57:347–351.
 462 https://doi.org/10.1001/archneur.57.3.347
- 26. Hunter JD (2007) Matplotlib: A 2D graphics environment. J Comput Inf Sci Eng 9:90–95.
 https://doi.org/10.1109/MCSE.2007.55
- 465 27. Kaivola K et al (2023) Genome-wide structural variant analysis identifies risk loci for non 466 Alzheimer's dementias. Cell Genom 3. https://doi.org/10.1016/j.xgen.2023.100316
- 467 28. Kaivola K, Shah Z, Chia R, International LBD Genomics Consortium, Scholz S (2022) Genetic
 468 evaluation of dementia with Lewy bodies implicates distinct disease subgroups. Brain
 469 145:1757–1762. https://doi.org/10.1093/brain/awab402

- 470 29. Karczewski KJ, Francioli LC, Tiao G et al (2020) The mutational constraint spectrum
 471 quantified from variation in 141,456 humans. Nature 581:434–443.
 472 https://doi.org/10.1038/s41586-020-2308-7
- 473 30. Kotzbauer PT, Trojanowski JQ, Lee VMY (2001) Lewy body pathology in Alzheimer's disease.
 474 J Mol Neurosci 17:225–232. https://doi.org/10.1385/JMN:17:2:225
- 475 31. Koutsodendris N, Nelson MR, Rao A, Huang Y (2022) Apolipoprotein E and Alzheimer's
 476 Disease: Findings, Hypotheses, and Potential Mechanisms. Annu Rev Path 17:73–99.
 477 https://doi.org/10.1146/annurev-pathmechdis-030421-112756
- 478 32. Lantero Rodriguez J, Karikari TK, Suárez-Calvet M et al (2020) Plasma p-tau181 accurately
 479 predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves
 480 the clinical characterisation of cognitive decline. Acta Neuropathol 140:267–278.
 481 https://doi.org/10.1007/s00401-020-02195-x
- 482 33. Le Guen Y, Belloy ME, Napolioni V et al (2021) A novel age-informed approach for genetic
 483 association analysis in Alzheimer's disease. Alzheimer's Res Therapy 13.
 484 https://doi.org/10.1186/s13195-021-00808-5
- 485 34. Leverenz JB, Fishel MA, Peskind ER et al (2006) Lewy Body Pathology in Familial Alzheimer
 486 Disease: Evidence for Disease- and Mutation-Specific Pathologic Phenotype. Arch Neurol
 487 63:370–376. https://doi.org/10.1001/archneur.63.3.370
- 488 35. Machiela MJ, Chanock SJ (2015) LDlink: a web-based application for exploring population489 specific haplotype structure and linking correlated alleles of possible functional variants.
 490 Bioinformatics 31:3555–3557. https://doi.org/10.1093/bioinformatics/btv402
- 491 36. Majbour N, Aasly J, Abdi I, Ghanem S, Erskine D, van de Berg W, El-Agnaf O (2022) Disease492 associated α-synuclein aggregates as biomarkers of Parkinson disease clinical stage.
 493 Neurology 99. https://doi.org/10.1212/WNL.00000000201199
- 494 37. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM (2010) Robust relationship
 495 inference in genome-wide association studies. Bioinformatics 26:2867–2873.
 496 https://doi.org/10.1093/bioinformatics/btq559
- 497 38. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J et al (2017) Diagnosis and
 498 management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.
 499 Neurology 89:88–100. https://doi.org/10.1212/WNL.00000000004058
- 39. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ et al (1991) The Consortium to Establish a
 Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic
 assessment of Alzheimer's disease. Neurology 41:479–486.
 https://doi.org/10.1212/wnl.41.4.479
- 40. Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S et al (2019) Identification
 of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis
 of genome-wide association studies. Lancet Neurol 18:1091–1102.
 https://doi.org/10.1016%2FS1474-4422(19)30320-5
- 41. Nelson PT, Alazufoff I, Bigio EH, Bouras C, Braak H et al (2012) Correlation of Alzheimer
 Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature. J
 Neuropathol Exp Neurol 71:362–381. https://doi.org/10.1097/nen.0b013e31825018f7

| 511 | 42. Pillai JA, Bena J, Bonner-Jackson A, Leverenz JB (2021) Impact of APOE ε4 genotype on initial |
|-----|---|
| 512 | cognitive symptoms differs for Alzheimer's and Lewy body neuropathology. Alzheimer's Res |
| 513 | Therapy 13. https://doi.org/10.1186/s13195-021-00771-1 |
| 514 | 43. Poggiolini I. Gupta V. Lawton M. Lee S. El-Turabi A et al (2022) Diagnostic value of |

- 43. Poggiolini I, Gupta V, Lawton M, Lee S, El-Turabi A et al (2022) Diagnostic value of
 cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. Brain 145:584–
 595. https://doi.org/10.1093/brain/awab431
- 44. Rahimi J, Kovacs GG (2014) Prevalence of mixed pathologies in the aging brain. Alzheimer's
 Res Therapy 6. https://doi.org/10.1186/s13195-014-0082-1
- 45. Rizzo G, Arcuti S, Copetti M, Alessandria M, Savica R et al (2018) Accuracy of clinical diagnosis
 of dementia with Lewy bodies: a systematic review and meta-analysis. J Neurol Neurosurg
 Psychiatry 89:358–366. https://doi.org/10.1136/jnnp-2017-316844
- 46. Robinson JL, Lee EB, Xie SX, Rennert L, Suh E et al (2018) Neurodegenerative disease
 concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain
 141:2181–2193. https://doi.org/10.1093/brain/awy146
- 47. Russo MJ, Orru CD, Concha-Marambio L et al (2021) High diagnostic performance of
 independent alpha-synuclein seed amplification assays for detection of early Parkinson's
 disease. acta neuropathol commun 9. https://doi.org/10.1186/s40478-021-01282-8
- 48. Sabir MS, Blauwendraat C, Ahmed S, Serrano GE, Beach TG et al (2019) Assessment of APOE
 in atypical parkinsonism syndromes. Neurobiol Dis 127:142–146.
 https://doi.org/10.1016%2Fj.nbd.2019.02.016
- 49. Savica R, Beach TG, Hentz JG et al (2019) Lewy body pathology in Alzheimer's disease: A
 clinicopathological prospective study. Acta Neurol Scand 139:76–81.
 https://doi.org/10.1111/ane.13028
- 534 50. Skogseth R, Hortobágyi T, Soennesyn H, Chwiszczuk L, Ffytche D et al (2017) Accuracy of
 535 clinical diagnosis of dementia with Lewy bodies versus neuropathology. J Alzheimer's Dis
 536 59:1139–1152. https://doi.org/10.3233/jad-170274
- 537 51. Thal DR, Rub U, Orantes M, Braak H (2002) Phases of Aβ-deposition in the human brain and
 538 its relevance for the development of AD. Neurology 58:1791–1800.
 539 https://doi.org/10.1212/WNL.58.12.1791
- 540 52. Tsuang D, Leverenz JB, Lopez OL et al (2013) APOE ϵ4 Increases Risk for Dementia in Pure
 541 Synucleinopathies. JAMA Neurol 70:223–228.
 542 https://doi.org/10.1001/jamaneurol.2013.600
- 543 53. Twohig D, Nielsen HM (2019) α-synuclein in the pathophysiology of Alzheimer's disease. Mol
 544 Neurodegeneration 14. https://doi.org/10.1186/s13024-019-0320-x
- 545 54. Walker JM, Richardson TE (2023) Cognitive resistance to and resilience against multiple
 546 comorbid neurodegenerative pathologies and the impact of APOE status. J Neuropathol Exp
 547 Pathol 82:110–119. https://doi.org/10.1093/jnen/nlac115
- 54855. Willer CJ, Li Y, Abecasis GR (2010) METAL: fast and efficient meta-analysis of genomewide549associationscans.Bioinformatics26:2190–2191.550https://doi.org/10.1093/bioinformatics/btq340

- 55156. Yin L, Zhang H, Tang Z, Xu J, Yin D et al (2021) rMVP: A Memory-efficient, Visualization-552enhanced, and Parallel-accelerated Tool for Genome-wide Association Study. Genomics
- 553Proteomics Bioinformatics 19:619–628. https://doi.org/10.1016/j.gpb.2020.10.007
- 554 57. Zhao N et al (2020) APOE4 exacerbates alpha-synuclein pathology and related toxicity 555 independent of amyloid. Sci Transl Med 12. https://doi.org/10.1126/scitranslmed.aay1809



Figure 1. Schemes used to classify individuals. a. Criteria from Tsuang et al. (2013) [52]. b. Criteria from Kaivola et al. (2022) [28]. c. Criteria in the present study.



Figure 2. Manhattan plots of genetic association with pathology contrasts. a. Association with 561 AD+LB+ pathology versus AD-LB- pathology. **b.** Association with AD+LB- pathology versus AD-LB-562 pathology. c. Association with AD-LB⁺ pathology versus AD-LB⁻ pathology. d. Association with 563 AD+LB+ pathology versus AD+LB- pathology. Variants at two novel loci exhibited genome-wide 564 565 significant associations in the AD-LB+ versus AD-LB- analysis (rs112017605 on both an intron of AC024598.1 and an intron of AC067752.1 on chromosome 10 and rs116691607 on an intron of BLMH 566 567 on chromosome 17) (c; Suppl. Table 2), but we do not discuss these candidates in the main text 568 because neither was flanked by a set of nearby variants in linkage disequilibrium, raising concern 569 that these could be spurious signals.

Table 1 Demographics from participants included in the current study, pathologically evaluated in the National Alzheimer's Coordinating Center (NACC) or Rush University Medical Center databases. AD+LB+ corresponds to AD-LB co-pathology individuals, AD+LB- corresponds to

sole AD pathology individuals, AD-LB+ corresponds to sole LB pathology individuals, and AD-LBcorresponds to individuals with neither pathology. AAD is age-at-death, reported as mean ± standard
deviation.

576

| | Overall | | | | NACC | | | Rush | | | |
|--------|---------|-------------|------------|-------|-------------|------------|-----|-----------|------------|--|--|
| | Ν | N female | AAD | N | N female | AAD | N | N female | AAD | | |
| AD+LB+ | 1,072 | 544 (51%) | 82.9 ± 9.3 | 851 | 395 (46%) | 80.8 ± 8.9 | 221 | 149 (67%) | 91.0 ± 5.8 | | |
| AD+LB- | 2,492 | 1,435 (58%) | 83.5 ± 9.4 | 1,973 | 1,055 (53%) | 81.5 ± 9.2 | 519 | 380 (73%) | 91.1 ± 5.7 | | |
| AD-LB+ | 158 | 76 (48%) | 86.6 ± 8.1 | 84 | 34 (40%) | 85.4 ± 8.9 | 74 | 42 (57%) | 88.0 ± 6.8 | | |
| AD-LB- | 1,263 | 706 (56%) | 87.3 ± 8.1 | 724 | 376 (52%) | 86.8 ± 8.8 | 539 | 330 (61%) | 87.9 ± 7.1 | | |

578 **Table 2.** *APOE-* ϵ **4 allele frequency by pathology category.** The second and third columns indicate 579 the frequency of *APOE-* ϵ **4** among the NACC or Rush individuals in each category. Frequencies are 580 reported as count of *APOE-* ϵ **4** alleles out of total allele count.

581

| | Overall | NACC | Rush |
|--------|---------------------|---------------------|-------------------|
| AD+LB+ | 744/2,144 (34.7%) | 662/1,702 (38.9%) | 82/442 (18.6%) |
| AD+LB- | 1,685/4,984 (33.8%) | 1,492/3,946 (37.8%) | 193/1,038 (18.6%) |
| AD-LB+ | 28/316 (8.9%) | 20/168 (11.9%) | 8/148 (5.4%) |
| AD-LB- | 249/2,526 (9.9%) | 166/1,448 (11.5%) | 83/1,078 (7.7%) |

Table 3. Number of individuals in pathology categories across analyses. Not all classifications
were necessarily pathologically confirmed (Suppl. Table 1). First column: our study cohort. Next
two columns: our preliminary cohort (before the removal of individuals not classified by our criteria)
classified using literature criteria (Fig. 1a-b) [52, 28]. Remaining columns: category sizes in
literature cohorts [52, 28, 13, 2, 10, 14, 18, 24, 46, 48]. For Beecham *et al.*, Robinson *et al.*, and Sabir *et al.*, only analyses of *APOE-ε*4-associated risk for LB pathology or dementia are considered [2, 46,
For Guerreiro *et al.*, we describe the larger discovery cohort [24].

590

| | Current sample | Initial sample × Tsuang <i>et al.</i> (2013) criteria | Initial sample × Kaivola <i>et al.</i> (2022) criteria | Tsuang <i>et al.</i> (2013) | Kaivola <i>et al.</i> (2022) | Chia <i>et al.</i> (2021) | |
|--------------|-------------------|---|--|-----------------------------------|------------------------------------|---------------------------------|--|
| AD+LB+ | 1,072 | 916 | 695 | 224 | 66/341ª | ? | |
| AD+LB- | 2,492 | 2,492 | 3,493 | 244 | 0 | 0 | |
| AD-LB+ | 158 | 316 | 158 | 91 | 88 | ? | |
| AD-LB- | 1,263 | 1,358 | 908 | 269 | 2,928 | 4,027 | |
| LB+ <i>b</i> | N/A | N/A | N/A | N/A | N/A | 2,591 | |
| LB- <i>b</i> | N/A | N/A | N/A | N/A | N/A | N/A | |

591

| | Beecham <i>et al.</i> (2014) | Bras <i>et al.</i> (2014) | Chung <i>et al.</i> (2015) | Dickson <i>et al.</i> (2018) | Guerreiro <i>et al.</i> (2018) | Robinson <i>et al.</i> (2018) | Sabir <i>et al.</i> (2019) |
|--------------|------------------------------------|---------------------------------|----------------------------------|------------------------------------|--------------------------------------|-------------------------------------|----------------------------------|
| AD+LB+ | ? | ? | 215 | 10/27/115/19/ 111/209ª | ? | 130/96 ^{a,c} | ? |
| AD+LB- | ? | 0 | 316 | 0 | 0 | 16/60 ^a | 0 |
| AD-LB+ | ? | ? | 0 | 46/80/33 ^a | ? | 10/12/22ª | ? |
| AD-LB- | ? | 2,624 | 0 | 660 | 3,791 | 0 | 591 |
| LB+ <i>b</i> | 2,391 | 667 | N/A | N/A | 1,216 | N/A | 525 |
| LB- <i>b</i> | 1,135 | N/A | N/A | N/A | N/A | N/A | N/A |

592

593 ^aIn Dickson *et al.*, the AD+LB+ individuals were subdivided into individuals with moderate or high 594 AD pathology and brainstem, transitional, or diffuse LB pathology; the subgroup sizes are listed 595 in the order moderate-brainstem, moderate-transitional, et cetera [18]. In Robinson et al., the 596 AD+LB+ individuals were subdivided into individuals with primary intermediate or high AD pathology and secondary LB pathology and individuals with primary brainstem, limbic, or 597 598 neocortical LB pathology [46]. In Kaivola et al., the AD⁺LB⁺ individuals were subdivided into 599 individuals with intermediate or high AD pathology [28]. A separate analysis was performed on 600 each subgroup in each of these three studies. ^bThese rows are populated only if an analysis was 601 performed on an LB⁻ or LB⁺ group. In this case the sizes of the corresponding subgroups are

602 marked as unknown (*e.g.*, AD^+LB^+ and AD^-LB^+ if LB^+ is known). The six subgroups of this

603 category were consolidated into two subgroups analyzed separately for association of *APOE*- ε 4

with AD co-pathology versus sole intermediate or high AD pathology or LB co-pathology versus

sole brainstem, limbic, or neocortical LB pathology: 130 individuals with primary AD pathology
and secondary LB pathology and 96 with primary LB pathology and secondary AD pathology,

607 respectively [46].

Table 4. Association of *APOE-ε*4 (rs429358) with different pathology contrasts. The first column corresponds to the current study, while the following two columns correspond to results obtained using the current sample using literature criteria to classify participants into pathology groups (Fig. 1a-b) [52, 28]. The other columns correspond to results reported in the literature [52, 28, 13, 2, 10, 14, 18, 24, 46, 48]. Effect sizes are reported as OR with 95% confidence interval [CI] and significance (*P*-value).

| | Current sample | Initial sample × Tsuang <i>et al.</i> (2013) criteria | Initial sample × Kaivola <i>et al.</i> (2022) criteria | Reported by Tsuang <i>et al.</i> (2013) | Reported by Kaivola <i>et al.</i> (2022) | Reported by Chia <i>et al.</i> (2021) |
|----------------------|--------------------------------|---|--|---|---|---|
| AD+LB+ vs. AD-LB- | 4.24 [3.52 5.10] (1.49e-52) | 3.86 [3.23 4.63] (5.10e-49) | 5.02 [3.97 6.35] (2.21e-41) | 12.6 [8.1 19.8] (2.1e-28) | 2.31 [1.40 3.83] (1.1e-03) 4.25 [3.35 4.39] (1.29e-32) | N/A |
| AD+LB- vs. AD-LB- | 4.22 [3.60 4.96] (1.41e-69) | 3.55 [3.07 4.12] (3.27e-64) | 4.66 [3.87 5.60] (3.90e-60) | 9.9 [6.4 15.3] (1.2e-24) | N/A | N/A |
| AD-LB+ vs. AD-LB- | 0.93 [0.60 1.43] (7.34e-01) | 1.46 [1.12 1.90] (5.47e-03) | 1.17 [0.74 1.84] (4.95e-01) | 6.1 [3.5 10.5] (1.3e-10) | 0.75 [0.43 1.30] (3.1e-01) | N/A |
| AD+LB+ vs. AD+LB- | 1.01 [0.90 1.13] (8.33e-01) | 1.09 [0.97 1.22] (1.66e-01) | 1.00 [0.88 1.14] (9.93e-01) | N/A | N/A | N/A |
| LB+ vs. AD-LB- | N/A | N/A | N/A | N/A | N/A | 2.45 [2.22 2.74] (4.65e-63) |
| LB+ vs. LB- | N/A | N/A | N/A | N/A | N/A | N/A |
| LB+ vs. AD-LB+ | N/A | N/A | N/A | N/A | N/A | N/A |
| AD+ vs. AD+LB- | N/A | N/A | N/A | N/A | N/A | N/A |

| | Reported by Beecham <i>et al.</i> (2015) | Reported by Bras et al. (2014) (at rs769449) ^b | Reported by Chung <i>et al.</i> (2015) | Reported by Dickson <i>et al.</i> (2018) | Reported by Guerreiro <i>et al.</i> (2018) | Reported by Robinson <i>et al.</i> (2018) | Reported by Sabir <i>et</i> <i>al.</i> (2019) |
|----------------------|---|---|---|--|---|--|---|
| AD+LB+ vs. AD-LB- | N/A | N/A | N/A | 1.88 [0.37 9.49] (4.5e-01) 3.42 [1.48 7.92] (4e-03) 3.74 [2.34 5.97] (4e-08) 9.37 [2.90 30.24] (2e-04) 5.58 [3.38 9.20] (2e-11) 6.96 [4.70 10.29] (3e-22) | N/A | N/A | N/A |
| AD+LB- vs. | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| AD-LB+ vs. AD-LB- | N/A | N/A | N/A | 0.30 [0.10 0.87] (2.7e-02) 0.73 [0.40 1.34] (0.31) 3.46 [1.66 7.22] (1e-03) | N/A | N/A | N/A |
| AD+LB+ vs. AD+LB- | N/A | N/A | (3e-02) | N/A | N/A | N/A | N/A |
| LB⁺ vs. AD-LB- | N/A | 2.711 [2.313 3.177] (7.09e-35) | N/A | N/A | 2.40 [2.14 2.70] (1.05e-48) | N/A | 2.94 [2.34 3.71] (6.6e-20) |
| LB⁺ vs. LB⁻ | 1.63 [1.52 1.76] (2.8e-11) | N/A | N/A | N/A | N/A | N/A | N/A |
| LB+ vs. AD-LB+ | N/A | N/A | N/A | N/A | N/A | 2.25 [0.25 19.90] (4.66e-01) 8.69 [0.70 107.39] (9.2e-01) 9.32 [2.12 40.95] (3e-03) | N/A |
| AD+ vs. AD+LB- | N/A | N/A | N/A | N/A | N/A | 0.71 [0.17 2.95] (6.4e-01) 0.93 [0.48 1.82] (8 3e-01) | N/A |

617 ^aIn Kaivola *et al.*, Dickson *et al.*, and Robinson *et al.*, analyses were performed on separate

subgroups [28, 18, 46]. The order of the results is the same as the order in which the

619 corresponding subgroups were listed in **Suppl. Table 1**. $^{b}APOE-\varepsilon 4$ and rs769449 reported in [13]

620 and [10] are in linkage disequilibrium ($R^2 = 0.766$).

621 Table 5. Association of rs4663105 on the BIN1 locus with different pathology contrasts. The

622 first column corresponds to the current study, while the following two columns correspond to results

623 obtained using the current sample using literature criteria to classify participants into pathology

624 groups (**Fig. 1a-b**) [52, 28]. The last column corresponds to a result reported in the literature [13].

625 Effect sizes are reported as OR with 95% confidence interval [CI] and significance (*P*-value).

626

| | Current study | Initial sample × Tsuang <i>et al.</i> (2013) criteria | Initial sample × Kaivola <i>et al.</i> (2022) criteria | Reported by Chia <i>et al.</i> (2021) (at rs6733839) ^a |
|-------------------|------------------|---|--|--|
| AD+LB+ vs. | 1.53 [1.35 1.75] | 1.55 [1.35 1.77] | 1.56 [1.33 1.82] | N/A |
| AD-LB- | (1.35e-10) | (2.19e-10) | (1.99e-08) | |
| AD+LB- vs. | 1.40 [1.26 1.56] | 1.36 [1.23 1.51] | 1.36 [1.22 1.52] | N/A |
| AD-LB- | (6.51e-10) | (4.45e-09) | (6.32e-08) | |
| AD-LB+ vs. | 1.10 [0.85 1.41] | 1.20 [1.00 1.44] | 1.11 [0.86 1.43] | N/A |
| AD-LB- | (4.76e-01) | (4.81e-02) | (4.18e-01) | |
| AD+LB+ vs. | 1.13 [1.02 1.25] | 1.14 [1.03 1.28] | 1.20 [1.07 1.35] | N/A |
| AD+LB- | (1.91e-02) | (1.57e-02) | (2.10e-03) | |
| LB+ vs. AD-LB- | N/A | N/A | N/A | 1.25 [1.16 1.35] (4.16e-09) |

ars4663105 and rs6733839 reported in [13] are in linkage disequilibrium ($R^2 = 0.8968$).

628 Table 6. Known Alzheimer's disease risk loci reported in Bellenguez et al. (2022) and known 629 Parkinson's disease risk loci reported in Chang et al. (2017) and Nalls et al. (2019) which are associated with the corresponding pathology contrasts at the nominal significance level (P < 630 0.05) [3, 12, 40]. For AD risk loci, associations with AD+LB+ vs. AD-LB- or AD+LB- vs. AD-LB- are 631 632 shown. For PD risk loci, associations with AD+LB+ vs. AD-LB-, AD-LB+ vs. AD-LB-, or AD+LB+ vs. AD+LBare shown. Chr:Pos:Minor:Major is chromosome, position (genome build hg38, GRCh38), and minor 633 634 allele and major allele in our study. Lit. effect is the effect size reported in the literature. MAF is the minor allele frequency in our study. Loci with results discordant in terms of direction of effect are 635 colored orange. 636

| Variant | Chr:Pos:Minor:Major | Locus | Lit. effect | Study | MAF | GWAS | Effect |
|-----------------|---------------------|------------------|---------------------------------|------------------------------------|-------|----------------------|--------------------------------|
| rs35749011 | 1:155162560:A:G | GBA | 1.72 [1.59 1.89] (2.59e-35) | Chang <i>et al.</i> (2017) | 1.3% | AD+LB+ vs. AD+LB- | 1.94 [1.24 3.06] (4.04e-03) |
| rs679515 | 1:207577223:T:C | CR1 | 1.13 [1.11 1.15] (7.20e-46) | Bellenguez <i>et al.</i> (2022) | 20.2% | AD+LB- vs. AD-LB- | 1.19 [1.04 1.36] (9.99e-03) |
| rs72777026 | 2:9558882:G:A | ADAM17 | 1.06 [1.04 1.08] (2.70e-08) | Bellenguez <i>et al.</i> (2022) | 14.2% | AD+LB+ vs. AD-LB- | 1.30 [1.09 1.56] (3.92e-03) |
| rs72777026 | 2:9558882:G:A | ADAM17 | 1.06 [1.04 1.08] (2.70e-08) | Bellenguez <i>et al.</i> (2022) | 14.2% | AD+LB- vs. AD-LB- | 1.17 [1.01 1.37] (4.19e-02) |
| rs6733839 | 2:127135234:T:C | BIN1 | 1.17 [1.16 1.19] (6.10e-118) | Bellenguez <i>et al.</i> (2022) | 41.9% | AD+LB+ vs. AD-LB- | 1.52 [1.34 1.74] (4.60e-10) |
| rs6733839 | 2:127135234:T:C | BIN1 | 1.17 [1.16 1.19] (6.10e-118) | Bellenguez <i>et al.</i> (2022) | 41.9% | AD+LB- vs. AD-LB- | 1.43 [1.29 1.60] (7.49e-11) |
| rs353116 | 2:165277122:T:C | SCN3A | 0.94 [0.92 0.96] (2.98e-08) | Chang <i>et al.</i> (2017) | 38.7% | AD+LB+ vs. AD-LB- | 0.85 [0.74 0.96] (1.14e-02) |
| rs10933431 | 2:233117202:G:C | INPP5D | 0.93 [0.92 0.95] (3.60e-18) | Bellenguez <i>et al.</i> (2022) | 21.8% | AD+LB- vs. AD-LB- | 0.79 [0.70 0.90] (3.09e-04) |
| rs34311866 | 4:958159:C:T | TMEM175/ DGKQ | 1.23 [1.20 1.27] (1.47e-50) | Chang <i>et al.</i> (2017) | 19.1% | AD-LB+ vs. AD-LB- | 1.33 [1.01 1.75] (4.29e-02) |
| rs34311866 | 4:958159:C:T | TMEM175/ DGKQ | 1.23 [1.20 1.27] (1.47e-50) | Chang <i>et al.</i> (2017) | 19.1% | AD+LB+ vs. AD+LB- | 1.22 [1.07 1.38] (2.83e-03) |
| rs6846529 | 4:11023507:C:T | CLNK/ HS3ST1 | 1.07 [1.05 1.08] (2.20e-17) | Bellenguez <i>et al.</i> (2022) | 28.0% | AD+LB- vs. AD-LB- | 1.15 [1.02 1.29] (2.12e-02) |
| rs11724635 | 4:15735478:C:A | FAM200B/ CD38 | 0.90 [0.88 0.92] (1.22e-19) | Chang <i>et al.</i> (2017) | 45.3% | AD-LB+ vs. AD-LB- | 0.71 [0.55 0.92] (9.03e-03) |
| rs356182 | 4:89704960:G:A | SNCA | 0.75 [0.74 0.77] (5.21e-123) | Chang <i>et al.</i> (2017) | 34.9% | AD-LB+ vs. AD-LB- | 0.74 [0.57 0.97] (2.60e-02) |
| rs11240336 0 | 5:14724304:A:T | ANKH | 1.09 [1.06 1.12] (2.30e-09) | Bellenguez <i>et al.</i> (2022) | 7.4% | AD+LB- vs. AD-LB- | 1.30 [1.06 1.59] (1.13e-02) |
| rs62374257 | 5:86927378:C:T | COX7C | 1.07 [1.05 1.09] (1.40e-15) | Bellenguez <i>et al.</i> (2022) | 22.8% | AD+LB+ vs. AD-LB- | 1.21 [1.04 1.41] (1.63e-02) |
| rs62374257 | 5:86927378:C:T | COX7C | 1.07 [1.05 1.09] (1.40e-15) | Bellenguez <i>et al.</i> (2022) | 22.8% | AD+LB- vs. AD-LB- | 1.26 [1.11 1.43] (3.83e-04) |
| rs6605556 | 6:32615322:G:A | HLA | 0.91 [0.90 0.93] (7.10e-20) | Bellenguez <i>et al.</i> (2022) | 16.0% | AD+LB+ vs. AD-LB- | 0.81 [0.69 0.96] (1.67e-02) |

| rs6605556 | 6:32615322:G:A | HLA | 0.91 [0.90 0.93] (7.10e-20) | Bellenguez <i>et al.</i> (2022) | 16.0% | AD+LB- vs. AD-LB- | 0.87 [0.76 1.00] (4.57e-02) |
|-----------------|------------------|-----------------------|--------------------------------|------------------------------------|-------|----------------------|--------------------------------|
| rs9275326 | 6:32698883:T:C | HLA-DRB6/ HLA-DQA1 | 0.85 [0.82 0.89] (1.26e-13) | Chang <i>et al.</i> (2017) | 9.8% | AD+LB+ vs. AD-LB- | 0.74 [0.60 0.91] (4.75e-03) |
| rs10947943 | 6:41036354:A:G | TREM2 | 0.94 [0.93 0.96] (1.10e-09) | Bellenguez <i>et al.</i> (2022) | 14.4% | AD+LB- vs. AD-LB- | 0.86 [0.75 1.00] (4.51e-02) |
| rs14333248 4 | 6:41161469:T:C | TREM2 | 1.41 [1.32 1.50] (2.80e-25) | Bellenguez <i>et al.</i> (2022) | 1.3% | AD+LB+ vs. AD-LB- | 1.99 [1.09 3.62] (2.50e-02) |
| rs14333248 4 | 6:41161469:T:C | TREM2 | 1.41 [1.32 1.50] (2.80e-25) | Bellenguez <i>et al.</i> (2022) | 1.3% | AD+LB- vs. AD-LB- | 1.87 [1.11 3.16] (1.97e-02) |
| rs785129 | 6:114291731:T:C | HS3ST5 | 1.04 [1.03 1.06] (2.40e-09) | Bellenguez <i>et al.</i> (2022) | 34.7% | AD+LB+ vs. AD-LB- | 1.19 [1.04 1.36] (1.25e-02) |
| rs13237518 | 7:12229967:A:C | TMEM106B | 0.96 [0.94 0.97] (4.90e-11) | Bellenguez <i>et al.</i> (2022) | 42.1% | AD+LB+ vs. AD-LB- | 1.23 [1.08 1.39] (1.29e-03) |
| rs13237518 | 7:12229967:A:C | TMEM106B | 0.96 [0.94 0.97] (4.90e-11) | Bellenguez <i>et al.</i> (2022) | 42.1% | AD+LB- vs. AD-LB- | 1.12 [1.01 1.24] (3.34e-02) |
| rs76928645 | 7:54873635:T:C | SEC61G | 0.93 [0.91 0.95] (1.60e-10) | Bellenguez <i>et al.</i> (2022) | 10.2% | AD+LB+ vs. AD-LB- | 0.81 [0.65 1.00] (4.84e-02) |
| rs7384878 | 7:100334426:C:T | ZCWPW1/ NYAP1 | 0.92 [0.91 0.94] (1.10e-26) | Bellenguez <i>et al.</i> (2022) | 29.3% | AD+LB- vs. AD-LB- | 0.85 [0.75 0.95] (5.45e-03) |
| rs591323 | 8:16839582:A:G | MICU3 | 0.91 [0.89 0.94] (2.38e-11) | Chang <i>et al.</i> (2017) | 27.2% | AD+LB+ vs. AD-LB- | 1.18 [1.02 1.36] (2.28e-02) |
| rs73223431 | 8:27362470:T:C | PTK2B | 1.07 [1.06 1.08] (4.00e-22) | Bellenguez <i>et al.</i> (2022) | 36.4% | AD+LB- vs. AD-LB- | 1.16 [1.04 1.29] (6.67e-03) |
| rs11787077 | 8:27607795:T:C | CLU | 0.91 [0.90 0.92] (1.70e-44) | Bellenguez <i>et al.</i> (2022) | 38.5% | AD+LB+ vs. AD-LB- | 0.85 [0.74 0.97] (1.33e-02) |
| rs11787077 | 8:27607795:T:C | CLU | 0.91 [0.90 0.92] (1.70e-44) | Bellenguez <i>et al.</i> (2022) | 38.5% | AD+LB- vs. AD-LB- | 0.89 [0.80 0.99] (3.43e-02) |
| rs7912495 | 10:11676714:G:A | ECHDC3 | 1.06 [1.05 1.08] (9.70e-19) | Bellenguez <i>et al.</i> (2022) | 46.1% | AD+LB+ vs. AD-LB- | 1.17 [1.03 1.33] (1.47e-02) |
| rs7912495 | 10:11676714:G:A | ECHDC3 | 1.06 [1.05 1.08] (9.70e-19) | Bellenguez <i>et al.</i> (2022) | 46.1% | AD+LB- vs. AD-LB- | 1.13 [1.01 1.25] (2.56e-02) |
| rs3851179 | 11:86157598:T:C | PICALM | 0.90 [0.89 0.92] (3.00e-48) | Bellenguez <i>et al.</i> (2022) | 35.2% | AD*LB- vs. AD-LB- | 0.86 [0.77 0.96] (7.92e-03) |
| rs11218343 | 11:121564878:C:T | SORL1 | 0.84 [0.81 0.87] (1.40e-21) | Bellenguez <i>et al.</i> (2022) | 3.6% | AD+LB- vs. AD-LB- | 0.72 [0.55 0.95] (2.12e-02) |
| rs329648 | 11:133895472:T:C | MIR4697 | 1.09 [1.07 1.12] (1.11e-13) | Chang <i>et al.</i> (2017) | 35.0% | AD+LB+ vs. AD+LB- | 0.88 [0.79 0.99] (2.62e-02) |
| rs6489896 | 12:113281983:C:T | TPCN1 | 1.08 [1.05 1.10] (1.80e-09) | Bellenguez <i>et al.</i> (2022) | 7.0% | AD+LB+ vs. AD-LB- | 1.31 [1.01 1.69] (4.04e-02) |
| rs11610045 | 12:132487182:A:G | FBRSL1 | 1.06 [1.04 1.08] (1.77e-10) | Nalls <i>et al.</i> (2019) | 48.2% | AD+LB+ vs. AD-LB- | 0.86 [0.76 0.98] (2.03e-02) |
| rs12147950 | 14:37520065:T:C | MIPOL1 | 0.95 [0.93 0.97] (3.54e-08) | Nalls et al. (2019) | 43.2% | AD-LB+ vs. AD-LB- | 1.29 [1.00 1.65] (4.59e-02) |
| rs17125924 | 14:52924962:G:A | FERMT2 | 1.10 [1.07 1.12] (8.30e-16) | Bellenguez <i>et al.</i> (2022) | 9.0% | AD+LB+ vs. AD-LB- | 1.27 [1.00 1.60] (4.95e-02) |
| rs17125924 | 14:52924962:G:A | FERMT2 | 1.10 [1.07 1.12] (8.30e-16) | Bellenguez <i>et al.</i> (2022) | 9.0% | AD+LB- vs. AD-LB- | 1.38 [1.14 1.67] (8.73e-04) |

| rs11761801 7 | 15:63277703:T:C | APH1B | 1.11 [1.09 1.13] (2.20e-25) | Bellenguez e <i>t al.</i> (2022) | 13.6% | AD+LB- vs. AD-LB- | 1.20 [1.03 1.40] (2.00e-02) |
|-----------------|-----------------|----------|--------------------------------|-------------------------------------|-------|----------------------|--------------------------------|
| rs1140239 | 16:30010081:T:C | DOC2A | 0.94 [0.93 0.96] (2.60e-13) | Bellenguez <i>et al.</i> (2022) | 38.0% | AD+LB+ vs. AD-LB- | 0.81 [0.71 0.93] (3.17e-03) |
| rs4784227 | 16:52565276:T:C | TOX3 | 1.09 [1.06 1.12] (9.75e-11) | Chang <i>et al.</i> (2017) | 24.7% | AD-LB+ vs. AD-LB- | 0.73 [0.54 0.98] (3.72e-02) |
| rs450674 | 16:79574511:C:T | MAF | 0.96 [0.95 0.98] (3.20e-08) | Bellenguez <i>et al.</i> (2022) | 36.8% | AD+LB- vs. AD-LB- | 0.87 [0.78 0.97] (1.01e-02) |
| rs56407236 | 16:90103687:A:G | PRDM7 | 1.11 [1.08 1.14] (6.50e-15) | Bellenguez <i>et al.</i> (2022) | 6.3% | AD+LB+ vs. AD-LB- | 1.38 [1.06 1.79] (1.67e-02) |
| rs616338 | 17:49219935:T:C | ABI3 | 1.32 [1.23 1.42] (2.80e-14) | Bellenguez <i>et al.</i> (2022) | 1.1% | AD+LB+ vs. AD-LB- | 2.35 [1.02 5.41] (4.47e-02) |
| rs12151021 | 19:1050875:A:G | ABCA7 | 1.10 [1.09 1.12] (1.60e-37) | Bellenguez <i>et al.</i> (2022) | 33.3% | AD+LB+ vs. AD-LB- | 1.23 [1.07 1.42] (3.69e-03) |
| rs12151021 | 19:1050875:A:G | ABCA7 | 1.10 [1.09 1.12] (1.60e-37) | Bellenguez <i>et al.</i> (2022) | 33.3% | AD+LB- vs. AD-LB- | 1.21 [1.08 1.35] (1.18e-03) |
| rs9304690 | 19:49950060:T:C | SIGLEC11 | 1.05 [1.03 1.07] (4.70e-09) | Bellenguez <i>et al.</i> (2022) | 25.0% | AD+LB+ vs. AD-LB- | 1.19 [1.03 1.37] (1.87e-02) |